Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ASSEMBLY BIOSCIENCES, INC. (ASMB)

Assembly Biosciences closes $115.0 million stock offering with full option exercise

Neutral Impact 3 of 5 financing Written later

Assembly Biosciences sold 3,358,602 common shares at $26.50 each and pre-funded warrants for up to 415,000 shares, and underwriters exercised in full a 566,040-share option on May 22, 2026. The offering closed on May 26, 2026, with the company reporting net proceeds of approximately $107.4 million. The company plans to use the proceeds for clinical development of pipeline candidates and general corporate purposes, and the new shares increase the number of shares outstanding for existing shareholders.

Key points

  • Closed May 26, 2026, including the full exercise of a 566,040-share underwriter option on May 22, 2026.
  • Common shares priced at $26.50; pre-funded warrants for up to 415,000 shares priced at $26.499 each.
  • Gross proceeds of approximately $115.0 million; net proceeds of approximately $107.4 million after underwriting discounts and offering expenses.
  • Executive officers and directors agreed to a 90-day lock-up, subject to exceptions and Guggenheim Securities' consent to sell.

The filing

CompanyASSEMBLY BIOSCIENCES, INC. (ASMB)
Form8-K, current report
Filed with the SECMay 26, 2026, 4:10 PM ET
Accession number0001193125-26-239277

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.